Nome ME, Euceda LR, Jabeen S, et al. - Researchers sought to determine the patients who will respond and benefit from antiangiogenic therapy via inscribing noninvasive monitoring of patient response to neoadjuvant chemotherapy given alone or in combination with anti-vascular endothelial growth factor (bevacizumab) in a randomized clinical trial. Metabolites and inflammation-related markers were measured in the patient's serum at four time points during neoadjuvant chemotherapy ± bevacizumab of receptor tyrosine-protein kinase erbB-2-negative breast cancers. The levels of several molecules indicated significant changes that were induced by bevacizumab, the most prominent being an increase in pentraxin 3 and von Willebrand factor (VWF). Response to chemotherapy alone or in combination with bevacizumab was reflected by serum levels of AXL, VWF and pulmonary and activation-regulated cytokine (PARC/CCL18). Observations revealed the correlation of VWF and growth-differentiation factor 15 tumor mRNA levels with their respective serum protein levels implying that these cytokines may be generated by tumors and outflow to the bloodstream while affecting the tumor microenvironment locally. Findings thereby emphasize the potential value of monitoring circulating levels of cytokines and metabolites during breast cancer therapy.